Table 1.

Characteristics of study participants, Shanghai Breast Cancer Study, Phase II

Participant characteristics	No. of subjects	Percentage	5-yr DFS	P
Age, y (N=1,045)
<45	213	20.4	0.81
45–49	321	30.7	0.88
50–59	323	30.9	0.82
≥ 60	188	18.0	0.83	0.16
Mean ± SD = 51.4 ± 8.3
Menopausal status (N=1,045)
Pre-menopause	570	54.6	0.84
Post-menopause	475	45.5	0.84	0.66
Family history of BC (N=1,045)
No	992	94.9	0.84
Yes	53	5.1	0.77	0.31
TNM stage (N=1,015)
0	24	2.4	0.96
I	324	31.9	0.95
IIa	334	32.9	0.89
IIb	219	21.6	0.76
III	107	10.5	0.55
IV	7	0.7	0.29	<0.01
Histological grade (N=1,038)
I	175	16.9	0.91
II	528	50.9	0.85
III	335	32.3	0.78	<0.01
Tumor size (N=981)
<=2 cm	437	44.6	0.91
>2 cm	544	55.5	0.78	<0.01
ER/PR/HER2 status (N=1,045)
ER Positive	655	62.7	0.86	0.08
PR Positive	642	61.4	0.86	0.05
HER2 Positive	313	30.4	0.80	0.12
Molecular type (N=845)
Luminal A	443	52.4	0.88
Luminal B	150	17.8	0.83
HER2	125	14.8	079
Triple negative	127	15.0	0.80	0.07
Cancer therapy received (N=1,044)
Chemotherapy	986	94.4	0.84	0.14
Radiotherapy	335	32.1	0.77	<0.01
Tamoxifen	566	54.2	0.86	0.16